KalVista Pharmaceuticals ... (KALV)
NASDAQ: KALV
· Real-Time Price · USD
15.82
0.62 (4.08%)
At close: Sep 05, 2025, 3:59 PM
15.82
0.00%
After-hours: Sep 05, 2025, 07:05 PM EDT
4.08% (1D)
| Bid | 13.55 |
| Market Cap | 790.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -183.44M |
| EPS (ttm) | -3.69 |
| PE Ratio (ttm) | -4.29 |
| Forward PE | -4.51 |
| Analyst | Buy |
| Ask | 16 |
| Volume | 1,037,549 |
| Avg. Volume (20D) | 1,244,075 |
| Open | 15.26 |
| Previous Close | 15.20 |
| Day's Range | 15.04 - 15.85 |
| 52-Week Range | 7.30 - 16.32 |
| Beta | -0.10 |
About KALV
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KALV
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for KALV stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
KalVista Pharmaceuticals Inc. is scheduled to release its earnings on
Sep 16, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+25.71%
KalVista Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
3 months ago
+9.49%
KalVista Pharmaceuticals shares are trading higher after the company announced new data and findings for sebetralstat.
2 months ago · seekingalpha.com
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just BeginningFDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy, providing a major competitive advantage over injectable options. EKTERLY's convenience an...
